Drug Reference

Semaglutide

semaglutide · Updated 2026-05-01 · Sources cited to FDA labeling

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist available under three brand names: Ozempic (subcutaneous injection

Sources
  • FDA label: Ozempic (semaglutide) injection, NDA 209637, revised 2024
  • FDA label: Wegovy (semaglutide) injection, NDA 215256, revised 2024
  • FDA label: Rybelsus (semaglutide) tablets, NDA 213051, revised 2024
  • SUSTAIN-6 trial: Marso et al., NEJM 2016;375:1834-1844
  • STEP-1 trial: Wilding et al., NEJM 2021;384:989-1002
  • SELECT trial: Lincoff et al., NEJM 2023;389:2221-2232
  • FLOW trial: Perkovic et al., NEJM 2024;391:109-121
  • FDA Drug Shortages Database, accessed January 2026
  • Novo Nordisk U.S. Prescribing Information and Patient Savings Program disclosures, January 2026

This site provides general information only and does not constitute medical advice. All content is sourced to FDA labeling, NIH publications, or peer-reviewed clinical trials. Always consult your prescriber before making any medication decision.